• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
Riociguat(625115-55-1)
Methyl [4,6-diaMino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyriMidin-5-yl]carbaMate
2-[1-(2-Fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyriMidine-4,5,6-triaMine(428854-24-4)
4,6-PyriMidinediaMine, 2-[1-[(2-fluorophenyl)Methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-(phenylazo)-
1H-Pyrazolo[3,4-b]pyridine-3-carboximidamide, 1-[(2-fluorophenyl)methyl]-, hydrochloride (1:1)
1-(2-Fluorobenzyl)-1H-pyrazolo[3,4-b]pyridine-3-carboximidamide(256376-68-8)

Canada's Concordia Accused of 6,000% Price Increase for Drug, Overcharging NHS by 100M Pounds

biospaceNovember 23, 2017

Tag: NHS , Concordia

Concordia International, the Canadian drug company, has overcharged the NHS by more than £100m in the past decade for a life-changing thyroid drug, according to Britain’s competition watchdog.

The Competition and Markets Authority (CMA) said it had provisionally found that Concordia had "abused its dominant position to overcharge the NHS" by hiking the price of liothyronine, used to treat patients with an underactive thyroid, by nearly 6,000% between 2007 and 2017.

The regulator said the NHS had spent more than £34m on the drug last year, up from about £600,000 in 2006.

Previous:FDA approves first implanted lens that can be adjusted after cataract surgery to improve vision with

Next:Merck to suspend filing Ebola vaccine for FDA approval until next year

Related News

Corvia Medical Achieves CE Certification for Atrial Shunt Under New EU MDR Standards

PRNewswireDecember 21, 2024

Corvia Medical, Inc.announced today that it has achieved CE certification for the Corvia® Atrial Shunt System under the latest EU Medical Device Regulations (EU MDR 2017/745).

Macrogen Consortium win tender for National Bio Big Data Project

PRNewswireDecember 23, 2024

SCG Cell Therapy partners A*STAR to accelerate RNA-based therapeutic development in Singapore

PRNewswireDecember 23, 2024

Canada's Concordia Accused of 6,000% Price Increase for Drug, Overcharging NHS by 100M Pounds | Pharmasources.com

Everest Medicines Announces Acceptance of the New Drug Application for VELSIPITY

Everest Medicines LimitedDecember 20, 2024

Everest Medicines announced NMPA acceptance of NDA for VELSIPITY(R) (etrasimod) to treat moderately to severely active UC.

You may like
More>>

Biotin-PEG4-NHS Ester

Biotin-PEG4-NHS Ester
Bis-PEG5-NHS Ester

Bis-PEG5-NHS Ester
CY5-SE; Cy5-NHS-Ester

CY5-SE; Cy5-NHS-Ester
Biotin-PEG8-NHS Ester

Biotin-PEG8-NHS Ester
Mal-PEG4-NHS Ester

Mal-PEG4-NHS Ester
m-PEG3-NHS ester

m-PEG3-NHS ester
Sulfo-NHS N-Hydroxysulfosuccinimide sodium salt

Sulfo-NHS N-Hydroxysulfosuccinimide sodium salt
m-PEG8-NHS ester

m-PEG8-NHS ester
Propargyl-PEG1-NHS ester

Propargyl-PEG1-NHS ester
NHS-activated Bestarose 4FF

NHS-activated Bestarose 4FF

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service